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Recent discoveries may change the way that multiple sclerosis (MS) is viewed, particularly with regard to the
reasons for the untoward immune response. The fact that myelin proteins are long-lived, and that by the time
we are adults, they are extensively degraded, alters our perspective on the reasons for the onset of
autoimmunity and the origin of MS. For example, myelin basic protein (MBP) from every human brain past
the age of 20 years, is so greatly modified, that it is effectively a different protein from the one that was laid
down in childhood. Since only a subset of people with such degraded MBP develop MS, a focus on
understanding the mechanism of immune responses to central nervous system (CNS) antigens and cerebral
immune tolerance appear to be worthwhile avenues to explore. In accord with this, it will be productive to
examine why all people, whose brains contain large quantities of a "foreign antigen", do not develop MS.
Importantly for the potential causation of MS, MBP from MS patients breaks down differently from the MBP
in aged controls. If the novel structures formed in these MS-specific regions are particularly antigenic, it could
help explain the origin of MS. If verified, these findings could provide an avenue for the rational synthesis of
drugs to prevent and treat MS.
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Abstract: Recent discoveries may change the way that multiple sclerosis (MS) is viewed, particularly
with regard to the reasons for the untoward immune response. The fact that myelin proteins are
long-lived, and that by the time we are adults, they are extensively degraded, alters our perspective
on the reasons for the onset of autoimmunity and the origin of MS. For example, myelin basic protein
(MBP) from every human brain past the age of 20 years, is so greatly modified, that it is effectively a
different protein from the one that was laid down in childhood. Since only a subset of people with
such degraded MBP develop MS, a focus on understanding the mechanism of immune responses
to central nervous system (CNS) antigens and cerebral immune tolerance appear to be worthwhile
avenues to explore. In accord with this, it will be productive to examine why all people, whose brains
contain large quantities of a “foreign antigen”, do not develop MS. Importantly for the potential
causation of MS, MBP from MS patients breaks down differently from the MBP in aged controls.
If the novel structures formed in these MS-specific regions are particularly antigenic, it could help
explain the origin of MS. If verified, these findings could provide an avenue for the rational synthesis
of drugs to prevent and treat MS.
Keywords: proteomics; age-related; isoaspartate; posttranslational modification; protein
decomposition; myelin basic protein
1. Introduction
Despite many years of research, the initiating events that lead to multiple sclerosis (MS) remain a
mystery. Several genes have been linked to a higher likelihood of developing MS, in particular, those
of the human leukocyte antigen (HLA) system. A consistent finding is the association between MS
and DR15 and DQ6 alleles of the major histocompatibility complex. Genome-wide association studies
have uncovered over 200 other genes outside of the HLA locus that increase the probability of MS to a
small extent [1,2].
Environmental contributors, such as infections, have been difficult to link directly with the onset
of MS. The role of microbiota is becoming increasingly of interest following the discovery that microbes
can trigger chronic immune disorders to dietary antigens, e.g., celiac disease [3], in addition to affecting
the outcome of neurological diseases [4]. In a remarkable linkage between cellular and microbiological
strands, it has been shown recently that tryptophan metabolites derived from gut bacteria can enter
the CNS where they act on transcription factors present in microglia and astrocytes [5]. In this way,
the gut can modulate inflammation in the CNS and affect the outcome of experimental autoimmune
encephalomyelitis (EAE), a common animal model of MS.
J. Clin. Med. 2018, 7, 281; doi:10.3390/jcm7090281 www.mdpi.com/journal/jcm
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2. Long-Lived Proteins and Autoimmunity
The reasons for developing autoimmunity in general, and MS in particular, are not well
understood. One feature that has been largely overlooked is the role of endogenous antigen
modification in triggering autoimmunity. In the bodies of adults, long-lived proteins are
ubiquitous [6–8]. In early life, such long-lived proteins are recognised as “self” however, over time,
they breakdown and this decomposition effectively creates new proteins that may be recognised by
the body as being “foreign”. The subject of this review are the structural changes to long-lived proteins
that occur inevitably with age. If these alterations are significant, new antigens are effectively created
within the body. Such processes may have particular relevance for the induction of MS, since myelin
proteins are long-lived proteins.
Over time, long-lived proteins undergo a plethora of modifications, such as racemisation,
truncation, deamidation, deimination, and cross-linking (reviewed in Ref. [9]) with each single
modification potentially being sufficient to break immune tolerance. Age-related modification of
proteins at a number of sites in the body may underlie the observation that the levels of autoantibodies
increase as a function of age [10]. In the case of another autoimmune condition, systemic lupus
erythematosus, [11], Mamula et al. have proposed a role for isoaspartate (isoAsp), an isomer of Asp
that is formed spontaneously in old proteins, [12] (see Figure 1) in generating the autoantibodies to
histones; another family of long-lived proteins.
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Figure 1. When old proteins in the body degrad , l structures are formed. L-Asp and L-Asn
residues can spontaneously convert over time to 4 isomeric forms, via a cyclic intermediate as illustrated.
An uncharged Asn becomes a mixture of four negatively charged Asp residues. Probably of greatest
impact as potential immune inducers are L-isoAsp and D-isoAsp. In the case of D-isoAsp the α-carbon
is racemised and the polypeptide chain is also extended by the insertion of a CH2 group, as highlighted
by the red bonds. In adult MBP, many positively charged Arg residues have been converted to neutral
citrulline residues. Together these abundant post translational modifications (PTMs) lead to protein
unfolding and the generation of novel antigens.
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3. Long-Lived Proteins and Multiple Sclerosis
Amongst the list of long-lived proteins are the structural proteins of myelin [7,9]. Indeed, these
may not turn over at all. Evidence for myelin proteins being long-lived comes from two main sources.
Firstly, stable-isotope labelling revealed little or no turnover [6]. Secondly, the degree of amino acid
racemisation of human MBP as a function of age [12] matched closely that of crystallin proteins from
the lens that are well-known not to be replaced during our lifetime [7]. Once the myelin sheath is laid
down in childhood, the major proteins within it, such as myelin basic protein (MBP), may be with
us for all of our lives. Although this is, in many ways, a remarkable finding, why does this matter,
and how could this play a role in the onset of human MS?
It turns out that proteins are not stable in a biological environment. Over time they break down.
To a large degree it seems that decomposition is largely non-enzymatic and that old proteins decay
due to the intrinsic instability of certain amino acid residues. Some reactions have been known for
years. For example, aspartic acid and asparagine racemise i.e., they change from the L-form to the
D-isomer, as well as converting to a different isomeric form, isoAsp (Figure 1) [13].
Other spontaneous reactions of old proteins include crosslinking [14,15], deamidation [16],
and peptide bond cleavage [17]. It should be noted that not all modifications to long-lived proteins are
spontaneous, for example, deimination of arginine residues has been attributed to the action of protein
arginine deiminase (Figure 1).
The many novel modifications of old proteins, and their time courses as a function of age [16,18],
have been documented in the human lens, where it is well-established that proteins do not turn over [8].
It is of interest that another age-related disease, cataract, can be traced to a greater degree of protein
modification at specific sites in lens crystallins [19,20]. If these reactions are extensive, the structure
and properties of the affected long-lived proteins change dramatically. This may have significant
consequences, for example, it is possible that the body may no longer recognise the altered protein as
being “self”. If this occurs, an immune response could be mounted against the modified old protein.
These subjects have been summarised in a recent review [9].
4. Myelin Basic Protein and Age
Proteomic analysis of the human cerebellum showed that MBP is highly modified in adults [9].
The extent of posttranslational modification is large, such that every region of the protein, showed some
form of covalent alteration. In addition, these changes are quantitatively major (Figure 2). The covalent
changes included deamidation of Asn and Gln residues, isomerisation of Asp, as well as deimination of
Arg residues to citrulline. Some of these changes increased with age. Most were abundant even at age
18, which was the youngest sample available from the brain bank. That extensive MBP modification
has taken place by such a young age may at first seem surprising, however the same phenomenon has
been observed in the human lens. In the lens, the great majority of posttranslational modifications
occur by age 20 [18]. Twenty years is, after all, equivalent to incubating a life-long protein at 37 ◦C for
more than 175,000 h!
It should be noted that the PTMs of adult myelin discussed in this article take place on MBP that
was significantly modified during development [21,22].
In accord with other long-lived proteins, one of the major changes characterised in adult human
MBP was the formation of isoAsp residues. This form of Asp is quite different from the normal
L-Asp that was present originally in the protein, and is due to the spontaneous formation of a cyclic
intermediate [13]. At each site of isoAsp formation from L-Asp (or L-Asn), the polypeptide backbone
has been extended by the insertion of a CH2 group (Figure 1). In reality, this particular modification
leads to an even greater alteration in protein structure because a common product is D-isoAsp. In this
case, the original L-amino acid site has been both extended and racemised. As well as creating novel
antigens, protein unfolding will accompany these chemical transformations.
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a foreign antigen and could commence an immune response. The precise cellular location of MBP is 
not yet clear. If it is partly extracellular then cellular degradation may not be required for immune 
priming. If MBP is an intracellular protein [23] then some cellular damage may be necessary. Not 
only does this provide an underlying mechanism for the autoimmune response, it also may explain 
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Figure 2. Myelin basic pr t i is highly modified in the adult human brain. Histogram showing the
relative abundances of some of the major sites of modification in MBP from the cerebellum in controls
and patients with MS. Three main types of modifications were observed: deimination of Arg (to form
citrulline), racemisation and isomerisation of Asp, and deamidation of Asn and Gln. It should be
noted that each site of Asn/Gln deamidation contains four Asp/Glu isomers due to the process of
spontaneous racemisation and isomerisation (see Figure 1). The average ages of the two groups were
controls 46 ± 22 years (n = 10) and MS patients 60 ± 12 years (n = 8). Shown are mean values ± SD.
Detailed subject data from Friedrich et al., 2016 [9].
5. Myelin Basic Protein and MS
MBP from an a ult, is ighly heterogeneous and is a different protein from the MBP that was
deposited originally n childhood. In one sense, an abundant new protein has been created in our
brain. Every MBP polypeptide in cerebellar myelin contains is Asp residues, s well as a number of
citrulline residues [9] and each of these amino acids is novel. These structures are not found in normal
proteins, including the original translated version of MBP.
It is not hard to imagine that in some cases the body may sense this ‘new’ form of MBP as being a
foreign antigen and could commence an immune response. The precise cellular location of MBP is
not yet clear. If it is partly extracellular then cellular degradation may not be required for immune
priming. If MBP is an intracellular protein [23] then some cellular damage may be necessary. Not only
does this provide an underlying mechanism for the autoimmune response, it also may explain why
many cases of MS become evident in the fourth decade of life [24]. Even by the 30s, MBP has been
almost totally transformed into a new protein. Although data on isoAsp formation and other PTMs in
the MBP from childre is lacking, it is likely that significant levels are present even in pre-teen years.
This is because in other long-lived proteins (LLPs), such as lens proteins, racemisation occurs most
rapidly in the first decade of life [18]. Therefore, the age-related changes to MBP and other myelin
proteins could even play a role in the genesis of pediatric MS.
6. My lin Basic Protein from MS Pa ients Is Different
If this ‘old protein’ hypothesis for the origin for MS is correct, why doesn’t everyone suffer
from the consequences of such an untoward immune attack, since the brains of all adults are full of
degraded MBP? One possibility is that the MBP from MS patients could be modified in a different
J. Clin. Med. 2018, 7, 281 5 of 12
way from the MBP in non-MS patients. Proteomic analysis showed that this was indeed the case.
Although cerebellum samples from both normal and MS patients contained highly modified MBP,
the MBP from MS patients was consistently different from the normal MBP at several sites (Figure 2).
At each site, the degree of change was greater in MS patients; the only exception being Arg 31.
In addition, once these MS-specific sites of modification were incorporated into a structure of MBP,
they appeared to be localised into clusters (Figure 3).
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Figure 3. MBP in MS patients is different fr BP in controls. Highli hted in red (Arg) and blue
(Asp) are 5 amino acid residues that differ significantly within a 19 amino acid sequence. This cluster
includes Arg 31, Asp 34, Arg 43, Asp 48, and Arg 49. For each site, the degree of change is greater
in the MS patients; the only exception being Arg 31. Statistical data are shown in Figure 2 and are
summarised from Friedrich et al. [9]. The model of MBP was generated using I-Tasser [25] and PyMOL
Molecular Graphics System was used to render th 3D structure.
One such cluster is a 19-residue sequence encompassing Arg 31 to Arg 49 (Figures 2 and 3).
This region includes Arg 31, Asp 34, Asp 48, Arg 43, and Arg 49 where in each instance, the extent of
modification is significantly greater in MS patients. The single exception is Arg 31, where it is lower.
Our hypothesis is that regions such as these may be particularly antigenic and could precipitate an
immune response tha leads ul imately to MS. There are precedents for ach f the major modifications
(i.e., isoAsp [9] and citrulline [26]) found to be more abundant within the MBP clusters from MS
patients, acting as potent antigens. In MBP from MS patients both of these immune promoters are
found close together in space [9] so there could well be a synergistic interaction of these novel amino
acids. In effect, aged MBP from MS patients may be ‘more antigenic’ than aged MBP of unaffected
individuals. It should be noted that other proteomic investigations have also detected differences
(e.g., in deami ation) betw en the MBP of control and MS patients [26]. These prot omic data are
bolstered by studies that have reported that myelin from MS patients differs from controls e.g., in being
‘developmentally immature’ [27].
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7. Considerations If MS Results from Age-Related Changes to MBP
There are a number of consequences that flow from the discovery that MBP is highly modified
with age and that some changes to MBP are characteristic of MS.
Firstly, if indeed human MS is an autoimmune disease provoked by an endogenously-formed
antigen, what, if any, biological processes exist to modulate the response? Can some protein
modifications be tolerated? After all, despite MBP being highly modified in all adults, only a small
fraction of people suffer disease symptoms.
To what extent does ongoing (in the adult) immune tolerance play a role in the body where there
is, in effect, a failure to respond to the formation of a major antigen that was absent at birth? Foxp3 + T
regulatory cells are likely to play an important role in this modulation. In addition, there are several
chaperone proteins present in the CNS (e.g., alpha crystallin) that can bind to modified, unfolded
proteins and in this way could cover potentially antigenic sites before they are recognised by the
immune surveillance machinery. Could this putative protective system be less effective in people who
go on to develop MS?
As with immunisation, the presence of a novel antigen alone may be insufficient to trigger a full
immune response. An adjuvant is necessary. Another immune-promoting event (e.g., an infection)
may be necessary for a complete response which ultimately leads to MS. In this regard, it is interesting
to note that bacterial and viral proteins contain unnatural amino acids such as D-isoAsp and D-isoGlu,
so molecular mimicry could play a role. It is known that there is a link between infection and MS [28]
and the presence of predisposing genes is also likely to be implicated.
T cells have long been thought to be implicated in MS pathogenesis, in particular the inflammation
associated with the condition. Recent studies have also highlighted the important contribution of B
cells. Evidence for a major role of B cells in MS is suggested by the clinical benefit derived by peripheral
B cell depletion using drugs such as rituximab, an anti-CD20 agent [29]. A possible way in which
modified MBP (and other myelin proteins) may elicit an immune response is depicted in Figure 4.
It is not yet known how normal individuals are able to maintain immunological tolerance towards
a new self-antigen (i.e., modified MBP) that is present in large amounts in the adult brain. As mentioned
above, there are some intriguing observations that suggest a role for peripheral B cell depletion in this
process. In an elegant study to determine whether B cell tolerance checkpoints are defective in MS
patients, it was discovered that most suffer from impaired peripheral B cell tolerance, resulting in the
accumulation of large numbers of autoreactive and polyreactive mature naive B cells, which express
white matter–reactive antibodies [30]. Aspects of B cell biology [31] and T cell interactions with respect
to MS have been more extensively reviewed elsewhere [32]. Interestingly, in surgical brain injury,
it has been found that immune tolerance can be induced by hepatic portal vein and intrathymic
injection of MBP [33]. Possibly, in individuals who are not affected by MS, continuous exposure to low
levels of modified MBP via the route depicted in Figure 4 may act in a similar manner to therapeutic
administration of a causative antigen as outlined by Verhagen et al. [34]. In theory, if such a mechanism
were impaired or disrupted, exposure to modified MBP may trigger MS.
J. Clin. Med. 2018, 7, 281 7 of 12
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8. Gender, MS, and Age-Related Changes to MBP
It is well known that MS affects more females than males. If MS can indeed be ascribed to the
body’s response to myelin deterioration in the brain, then it may be predicted that women could
harbour a greater degree of protein modification than men. Remarkably this has been observed for
MBP (Figure 5). The numbers analysed thus far are small, however the findings are in agreement with
a separate study of human MBP that showed higher levels of Asn deamidation, Gln deamidation,
and Arg deimination in women than men [35].
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9. Linkage between the CNS and the Periphery in MS
One reason for believing that an immune response is involved in the induction of MS comes
from animal studies. EAE is a widely studied animal model of human central nervous system (CNS)
demyelinating diseases, such as multiple sclerosis [36]. EAE can be induced in a number of species and
the most commonly used antigens for injection are spinal cord homogenates, myelin proteins such as
MBP, proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG), as well as peptides
derived from these proteins. Each results in a model with slightly different disease characteristics
regarding both immunology and pathology. EAE can also be induced by the passive transfer of T cells
reactive to these myelin antigens [37].
EAE demonstrates that once the body has been primed by exposure to a CNS antigen, that it can
respond with an attack on the brain. As has been recently reviewed by Louveau et al. [38] the CNS,
which was historically viewed as being immune privileged, is now recognized to be in continuous
communication with the rest of the body. One way in which an immune response to degraded
MBP could be initiated, is via the “glymphatic” system involving deep cervical lymph nodes [39].
The finding that MBP is long-lived, also provides a mechanism for how modified peptides derived
from it might travel from their source in the CNS to sites in the periphery where an immune response
could be initiated. Spontaneous cleavage of long-lived proteins at Ser [40] and Asn [13] could lead to
the release of modified MBP peptides from myelin into the cerebrospinal fluid (CSF) (Figure 4).
The various T cell responses in the CNS are controlled in a complex manner as summarised
in a recent comprehensive review [41] and structural organisation of the CNS plays a key role in
determining the details of the overall immune response [36]. Evidence in support of the scheme
outlined in Figure 4 is derived from several sources. For example, induction of apoptosis in
oligodendrocytes is accompanied by the accumulation of phagocytes containing myelin antigens
in the lymph nodes that drain the CNS [42]. In addition, oligodendrocyte death can cause CNS
antigens to drain from the CNS in amounts sufficient to induce a systemic T cell response against
MOG [43].
10. Autoantibodies and MS
There is c mpelling evidence from animal model systems that myelin antigens can act as drivers
for the induction of MS, and if this were true, it might be expected that MS patients display higher
levels of anti-myelin antibodies than unaffected individuals. The results of human antibody studies
in MS patients and controls have often been mixed [44,45]. The proteomic results may provide one
reason for this lack of consistency. Based on the proteomic data from human cerebellum, there is
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probably very little unmodified MBP left in normal adult brain. The degree of MBP modification is
simply so great. Preliminary data suggest that MBP from other brain regions is also highly modified.
Therefore, screening for antibodies to the MBP polypeptide as it was originally translated (and as it
once existed in childhood), may not be an appropriate method to assess whether MS patients have
clinically-relevant autoantibodies to adult myelin proteins.
Given the most recent proteomic data [9,26] that has uncovered brain proteins that are highly
altered in adults, a better question may be: are antibodies that recognise highly-modified MBP present
in MS patients? Antibodies may cross-react to varying degrees with the original unmodified MBP, or
possibly may not recognise it at all. Now that MS-specific sites on MBP have been characterised [9,26],
a search for antibodies to these particular sites in MS patients should be a priority. In other words,
using relevant antigens for antibody screens may be important. Unmodified (original) MBP may not
be the best choice and this factor could be one explanation for variability in the published results of
serum screening of MS patients for antibodies to MBP [44,45]. Our preliminary data indicate that
the other long-lived proteins in myelin (e.g., PLP and MOG [7]) have also been modified over time
and could potentially become new self-antigens, which have the potential to trigger autoimmunity.
The same caveats with regard to the screening for MS-relevant autoantibodies (and T cells) to these
proteins as outlined for MBP, may apply to them as well.
11. Cellular Aspects of MS
B and T cell responses to self-antigens are clearly important and mechanisms of central tolerance
for B cells have been reviewed [46]. Significant increases in the number of autoreactive B cells have
been observed in MS patients [47]. In general, it appears that B cell responses to single sites of PTM in
self-antigens are likely to be promiscuous, in the sense that the antibodies recognise both modified and
unmodified forms of the self-protein. Presumably this is because the amino acid sequences on either
side of the modification remain the same. On the other hand, T cell responses tend to be more specific
to the site of modification [48]. In the context of a B cell response in MS, it is important to recognise
that MBP has been modified at many sites [9].
Another hypothesis is that the modified MBP could act as a trigger of the innate immune response
by binding to pattern recognition receptors and/or damage-associated molecular pattern receptors to
drive inflammatory processes and lower activation thresholds of T and B cells.
12. A New Theory for MS
It is a corollary that if the extensive modification of MBP in the CNS, coupled with its drainage
into the periphery and the consequent induction of an immune response, (as illustrated in Figure 4),
is validated, it changes the way in which MS is viewed. For example, it renders largely unnecessary a
widely held hypothesis for the induction of MS, based on the sensitisation of autoreactive T cells by
non-CNS antigens derived from the periphery (e.g., molecular mimicry). In the hypothesis outlined in
this article, MS is triggered primarily by the formation of a novel endogenous antigen rather than by
the body’s altered response to an existing antigen.
13. Conclusions
With regard to the consequences, perhaps the most important for MS is that the existence of
MS-specific sites on a major myelin protein opens up the possibility of targeted drug design to prevent,
or treat, MS. Although it is not yet clear why MS presents in several forms, if MS does result from an
immune response to particular modified sites on MBP, then compounds that specifically recognise and
mask these sites could potentially offer a degree of protection. This may be the dawn of a new era in
the treatment of MS.
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